|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:alsoKnownAs
|
gptkb:crizotinib
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XE16
|
|
gptkbp:bioavailability
|
43%
|
|
gptkbp:CASNumber
|
877399-52-5
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:hasInChIKey
|
XGZVUEUWXADBQD-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C21H22Cl2FN5O
|
|
gptkbp:hasPatent
|
US Patent 7,858,612
|
|
gptkbp:hasSMILES
|
CC(C1=CC(=C(C(=C1)Cl)F)Cl)OCC2=CN=CC(=C2)C3=CN(N=C3)C
|
|
gptkbp:hasUNII
|
4I6E4J26OU
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PF-02341066
|
|
gptkbp:indication
|
gptkb:ROS1-positive_non-small_cell_lung_cancer
ALK-positive metastatic non-small cell lung cancer
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:IUPACName
|
3-[(1-(2,6-dichloro-3-fluorophenyl)ethoxy)methyl]-4-(1H-pyrazol-4-yl)pyridine
|
|
gptkbp:KEGGID
|
D09714
|
|
gptkbp:mechanismOfAction
|
ALK inhibitor
c-Met inhibitor
|
|
gptkbp:molecularWeight
|
449.34 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:DB08865
11626560
CHEMBL1173474
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
edema
constipation
fatigue
vision disorder
|
|
gptkbp:target
|
gptkb:c-Met
gptkb:ALK
ROS1
|
|
gptkbp:bfsParent
|
gptkb:Xalkori
|
|
gptkbp:bfsLayer
|
7
|